Pasithea Therapeutics
Announces Successful Treatment of First Patients in the UK with
Ketamine Infusion Therapy
-- Pasithea Clinics commences IV ketamine infusion therapy in
Knightsbridge, London, for the treatment of mental health disorders
--
Miami Beach, FL / October 27, 2021 -- InvestorsHub NewsWire
-- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced that Pasithea Clinics, its wholly owned
subsidiary has administered intravenous ("IV") ketamine therapy to
its first patients. In sub-anesthetic doses, ketamine has shown to
be highly effective at treating some psychiatric disorders, such as
treatment-resistant depression and post-traumatic stress
disorder.
"With major depression the leading cause of long-term
disability worldwide and mental health cases on the rise, new
therapies are urgently needed for patients who do not respond to
traditional treatments. Today, we are thrilled to announce that we
administered our first IV ketamine infusion therapy to patients
with treatment-resistant depression," stated Dr. Tiago Reis
Marques, CEO of Pasithea Therapeutics.
"This is a significant milestone for Pasithea Clinics and for
patients in the U.K. suffering with mental health conditions.
Decades of evidence supports the efficacy of ketamine in improving
symptoms for some mental health disorders, and studies have shown
that up to 70% of those who receive IV ketamine treatment will
eventually show a clinical response. We are excited to continue
providing treatment to patients deemed eligible to receive it,"
concluded Dr. Reis Marques.
Ketamine is a U.S. Food and Drug Administration ("FDA")
approved drug introduced as an anesthetic more than 50 years ago.
It has recently been repurposed
in significantly lower doses for the treatment of psychiatric
disorders and is now gaining ground as a promising
treatment for mental health disorders. In certain psychiatric conditions, such as
treatment-resistant depression ("TRD") and post-traumatic stress
disorder ("PTSD"), it has shown remarkable efficacy and a rapid and
sustained effect.
Pasithea has clinical partnerships to administer its IV
ketamine treatment. In the U.K., it has partnered with ZEN
Healthcare - a network of health clinics in London. In the U.S., it
has partnered with The IV Doc, Inc. to provide in-home IV ketamine
infusions. Both partnerships offer rapid exposure and expansion
opportunities.
About Pasithea
Therapeutics Corp.
Pasithea Therapeutics
Corporation is a U.S. biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders. With an experienced team of experts in the
fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of psychiatric
and neurological disorders. Pasithea is also focused on addressing
the needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward
Looking Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis
Marques
Chief Executive
Officer
E:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M.
Wilson
In-Site
Communications, Inc.
T:
212-452-2793
E:
lwilson@insitecony.com